Objectives: The primary objective of this article was to examine literature from the last 10 years surrounding cardiovascular risks associated with NSAID use. Methods: A systematic search was developed to include randomized control trials and systematic review meta-analyses that focused on the cardiovascular effects associated with NSAID use. Results: The search and screen identified 10 articles published in the last 10 years to be included in the review. Discussion: The most common cardiovascular risks studied in the included literature were hemodynamic effects and myocardial infarction. The evidence in the included studies suggests that concerns of adverse hemodynamic effects may be overstated with short-term NSAID use. Myocardial infarction was shown to be a very serious, but rare, side effect associated with NSAID use. Practitioners should weigh this risk when using NSAIDs in patients with an increased risk of MI at baseline. Other included studies described risks of Kounis syndrome, QTc prolongation, and potential reversal of right ventricular dysfunction in patients using NSAIDs.
Background: Shivering is an usual complication for parturients and anesthesiologists during spinal anethesia. we evaluate the efficacy of granisetron versus dexmedetomidine as a prophylaxis against postspinal shivering.Objective: The main aim was to assess the efficacy of granisetron and dexmedetomidine in lowering the incidence and severity of postspinal shivering.Study design: Prospective, randomized, comparative, double blind, controlled study and 75 parturients participated.Method: This trial was accomplished on 75 parturients, ASA I-II, aged from 20-45, who were planned for elective cesarean section under spinal anethesia and allocated into 3 groups at random 25 parturients in each group. After the umbilical cord was clamped (group C: received i.v. 0.9% saline) , (group D: received 0.3ug/kg i.v. dexmedetomidine) and (group G: received 3mg i.v. granistron). The incidence and severity of postspinal shivering was our primary outcome and was evaluated by Tsai and Chu scale (Tsai et al .,2001), while the secondary outcomes were the changes in vital signs of the parturient before and after administration of tested drugs, sedation score and the occurrence of adverse effects of tested drug.
Osteoarthritis (OA) is a common cause of pain and functional limitation. We compared the analgesic and functional outcomes of Ialoral® Forte, a nutraceutical formulation, with those of ultrasound-guided intra-articular triamcinolone in patients with hip or knee OA and baseline Numeric Rating Scale (NRS) ≤5. This retrospective single-center study included 60 patients (NRS≤5, Kellgren-Lawrence grade I-II) treated between June 2022 and January 2023. Group A received oral Ialoral® Forte (two tablets daily for 40 days); group B underwent two ultrasound-guided intraarticular corticosteroid injections 20 days apart. Pain intensity (NRS) and joint function (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]) were evaluated at baseline and at 20, 40, 60, and 90 days. Both treatments significantly reduced pain and improved joint function over time. No statistically significant differences were observed between groups (p>0.05). Oral Ialoral® Forte achieved comparable analgesic and functional outcomes to intra-articular corticosteroids, without injection-related risks or contraindications. Oral Ialoral® Forte represents a safe, effective, and non-invasive alternative to intra-articular corticosteroid injections for the management of mild to moderate osteoarthritis, providing similar short-term pain relief and functional recovery with excellent tolerability.
